| Catalog No. | Size | Price (USD) |
| 14552-RP01-100 | 100 µL | $147.96 |
| 14552-RP01-200 | 200 µL | $251.64 |
| 14552-RP01-400 | 400 µL | $355.32 |
General Information
| Product name | Anti-CRIP2 Antibody, Rabbit Polyclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CRIP2 |
| Immunogen | Recombinant Human CRIP2 protein (Catalog#14552-H20B) |
| Preparation | Produced in rabbits immunized with purified, recombinant Human CRIP2 (rh CRIP2; Catalog#14552-H20B; P52943; Met1-Pro208). Total IgG was purified by Protein A affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-CRIP Antibody; Anti-CRP2 Antibody; Anti-ESP1 Antibody
Background Information
| Full Name | cysteine-rich protein 2 |
| Description | CRIP2 is a putative transcription factor. It has a widespread tissue expression and is highly expressed in heart. CRIP2 contains two LIM zinc-binding domains. CRIP2 may participate in the differentiation of smooth muscle tissue. It also plays an important role in esophageal squamous cell carcinoma (ESCC) tumorigenesis. CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. It interacts with the NF-κB/p65 to inhibit its DNA-binding ability to the promoter regions of the major proangiogenesis cytokines critical for tumor progression, including IL6, IL8, and VEGF. In conclusion, we provide compelling evidence that CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. |
| References |
|
